# Cvs Caremark, Mt Prospect, IL – FDA Inspections

Source: https://www.keypedia.com/companies/cvs-caremark/6fd09836-d2a1-4518-9709-a29221b91243

> Inspection records and compliance data for Cvs Caremark in Mt Prospect, Illinois. 1 FDA inspection on record, last inspected August 23, 2011.

---

## Details

- Name: Cvs Caremark
- FEI Number: 3008609065
- Address Line 1: 800 Biermann Ct Ste B
- City: Mt Prospect
- State: Illinois
- Zip Code: 60056
- Country Name: United States
- Address: 800 Biermann Ct Ste B, Mt Prospect, Illinois 60056, United States
- Country: United States

## Related Documents

- FDA Inspection 741689 - Cvs Caremark - 2011-08-23 — classification: No Action Indicated (NAI), source: FDA, date: August 23, 2011

## Related Companies

- [Nancy L. Kuntz, M.D.](https://www.keypedia.com/companies/nancy-l-kuntz-md/8b239b68-0c72-4183-afaa-b7325dd80761)
- [Harmon's Drug Store](https://www.keypedia.com/companies/harmons-drug-store/f44ffbe3-eada-4b1e-bdf0-f297e900c754)
- [Barengolts, Elena, M.D.](https://www.keypedia.com/companies/barengolts-elena-md/282080bb-58f5-4342-bdef-122c02bcef51)
- [Celgene Corporation d.b.a. Abraxis Bioscience](https://www.keypedia.com/companies/celgene-corporation-dba-abraxis-bioscience/be6241ac-0d9c-45a2-8acb-5026fcde1b45)
- [Kamran Ayub](https://www.keypedia.com/companies/kamran-ayub/59b63f0f-44bb-40c7-829c-2a696c8e6aa4)
- [Merix Pharmaceutical Corporation](https://www.keypedia.com/companies/merix-pharmaceutical-corporation/ed26598a-ffcb-4345-8563-1a7f3f5911bf)
- [Vetter Development Services Usa Inc.](https://www.keypedia.com/companies/vetter-development-services-usa-inc/441a45c0-f67b-487a-b0e1-77e7b2062a3a)
- [Goldstein, Debra](https://www.keypedia.com/companies/goldstein-debra/f07a5110-2b96-452c-9e00-6a57e14e51ec)
- [Horizon Pharma, Inc.](https://www.keypedia.com/companies/horizon-pharma-inc/997bba50-59a2-418d-9261-cf54c6349fcd)
- [University of Illinois at Chicago IRB](https://www.keypedia.com/companies/university-of-illinois-at-chicago-irb/0417f616-4553-4798-b906-0a08f1c1a1bc)